首页> 外文期刊>Archives of pharmacal research >Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride.
【24h】

Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride.

机译:从每日一次盐酸地尔硫卓制剂的体外释放数据中预测体内血浆浓度-时间曲线的两种不同方法。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to employ two different mathematical approaches: first, a convolution approach using computer software; second, a mathematical calculation exploiting Wagner-Nelson calculation to predict in vivo plasma concentration-time profile from the in vitro release study for the once daily formulations of a model drug diltiazem hydrochloride. The once daily extended release tablets (120 mg) were prepared by the wet granulation technique. Ethanol or ethanolic solutions of ethylcellulose (N22), were used as granulating agents along with hydrophilic matrix polymers like hydroxypropyl methylcellulose (HPMC) (K 15M). The granules showed satisfactory flow properties, compressibility, moisture content and drug content. All the tablet formulations showed acceptable properties and complied with pharmacopeial limits. The in vitro drug release study revealed that formula F7-T which contains drug: HPMC ratio 1:1 and 20 mg of ethylcellulose was able to sustain the drug release for 24 h and satisfied the USP dissolution limits. Fitting the in vitro drug release data to Korsmeyer-Peppas equation indicated that the mechanism of drug release could be zero-order. The capsule formulation F14-C which consists of drug: HPMC ratio 1:2, 12 mg of ethylcellulose and 20 mg of polyox 100 showed in vitro drug release similar to the tablet F7-T using the similarity factor (f 2). The mechanism of drug release could be coupled diffusion, and polymer matrix relaxation. The percent dissolved data from the two formulations were used as input function to predict the in vivo plasma data by the two approaches (Convolution by Kinetica software and Wagner-Nelson calculation). The two methods were validated by prediction of plasma data from in vitro release data of FDA approved 300 mg extended release capsule. Prediction errors were estimated for Cmax and area under the curve (AUC) to determine the validity of the methods. The percent prediction error for each parameter is not exceeding 15%.
机译:这项研究的目的是采用两种不同的数学方法:首先,使用计算机软件进行卷积方法;其次,采用卷积方法。其次,利用Wagner-Nelson计算法进行数学计算,从模型药物盐酸地尔硫卓的每日一次制剂的体外释放研究中预测体内血浆浓度-时间曲线。通过湿法制粒技术制备每日一次的缓释片剂(120mg)。乙基纤维素(N22)的乙醇或乙醇溶液与亲水性基质聚合物(如羟丙基甲基纤维素(HPMC)(K 15M))一起用作制粒剂。颗粒显示令人满意的流动性,可压缩性,水分含量和药物含量。所有片剂均显示出可接受的性质,并符合药典限制。体外药物释放研究表明,配方F7-T含有1:1的药物:HPMC比例和20 mg的乙基纤维素,能够维持24小时的药物释放并满足USP溶出极限。将体外药物释放数据拟合到Korsmeyer-Peppas方程表明,药物释放的机制可能是零级的。由药物:HPMC比例为1:2、12 mg乙基纤维素和20 mg polyox 100组成的胶囊制剂F14-C在体外的药物释放与片剂F7-T相似,使用相似系数(f 2)。药物释放的机制可能与扩散和聚合物基质松弛有关。来自两种配方的溶解数据百分比被用作输入函数,以通过两种方法(通过Kinetica软件进行卷积和Wagner-Nelson计算)来预测体内血浆数据。通过根据FDA批准的300 mg缓释胶囊的体外释放数据预测血浆数据来验证这两种方法。估计Cmax和曲线下面积(AUC)的预测误差,以确定方法的有效性。每个参数的预测误差百分比不超过15%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号